glypican-4 Inhibitors
Glypican-4 inhibitors constitute a category of chemical compounds designed to target and modulate the activity of glypican-4, a cell surface heparan sulfate proteoglycan. Glypicans are a family of glycosylphosphatidylinositol (GPI)-anchored cell surface proteins that play a significant role in regulating cell signaling and developmental processes. Glypican-4, in particular, is expressed in various tissues and is known for its involvement in cellular communication and signal transduction. It interacts with several growth factors, morphogens, and other signaling molecules, serving as a co-receptor to enhance or restrict their signaling activities. Glypican-4 inhibitors are designed to interfere with these interactions, thereby potentially modulating various cellular processes influenced by glypican-4-mediated signaling.
The mechanisms by which glypican-4 inhibitors operate can differ based on their chemical structures and binding affinities. Some inhibitors may directly bind to glypican-4, blocking its ability to interact with specific ligands. Others may disrupt the lipid anchoring or glycosaminoglycan (GAG) chains of glypican-4, affecting its localization or signaling function. By targeting glypican-4, these compounds have the potential to influence a wide range of biological processes, including cell proliferation, differentiation, migration, and tissue development. Ongoing research is dedicated to uncovering the precise mechanisms and downstream effects of glypican-4 inhibition, contributing to our understanding of its significance in cellular biology and developmental processes.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Metformin | 657-24-9 | sc-507370 | 10 mg | $79.00 | 2 | |
Metformin, primarily known for its role in glucose metabolism, may also affect glypican-4 expression through its influence on cellular signaling pathways. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin, a well-known mTOR inhibitor, could potentially modulate glypican-4 expression as part of its broad effects on cell growth and proliferation. | ||||||
Lithium | 7439-93-2 | sc-252954 | 50 g | $214.00 | ||
Lithium, often used in neurological conditions, may affect glypican-4 expression through its impact on signaling pathways involved in neural development. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
5-Azacytidine, a compound that affects DNA methylation, could potentially modulate glypican-4 expression through epigenetic mechanisms. | ||||||
Doxorubicin | 23214-92-8 | sc-280681 sc-280681A | 1 mg 5 mg | $176.00 $426.00 | 43 | |
Doxorubicin might influence glypican-4 expression as part of its broad effects on DNA and RNA synthesis. | ||||||
Thalidomide | 50-35-1 | sc-201445 sc-201445A | 100 mg 500 mg | $111.00 $357.00 | 8 | |
Thalidomide, known for its effects on angiogenesis and immune modulation, may also impact glypican-4 expression through its influence on cellular signaling. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib, a proteasome inhibitor, could affect glypican-4 expression as part of its role in regulating protein degradation pathways. | ||||||
Cyclosporin A | 59865-13-3 | sc-3503 sc-3503-CW sc-3503A sc-3503B sc-3503C sc-3503D | 100 mg 100 mg 500 mg 10 g 25 g 100 g | $63.00 $92.00 $250.00 $485.00 $1035.00 $2141.00 | 69 | |
Cyclosporin A, an immunosuppressant, might modulate glypican-4 expression through its effects on T-cell signaling and cytokine production. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib, a kinase inhibitor, may influence glypican-4 expression by modulating various signaling pathways involved in cell growth and survival. | ||||||
Tamoxifen | 10540-29-1 | sc-208414 | 2.5 g | $272.00 | 18 | |
Tamoxifen, known for its role in hormone receptor modulation, could potentially affect glypican-4 expression through estrogen receptor pathways. | ||||||